百奥赛图-B（2315.HK）2025 年业绩快报点评 海外拓展+国内回暖驱动主业增长，全年业绩表现靓丽 glmszqdatemark [盈利预测与财务指标 Table_Forcast] 风险提示：海外经营风险，抗体开发不及预期风险，模式动物品系迭代风险。 | 单位/百万人民币 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入 | 980 | 1,379 | 1,849 | 2,422 | | 增长率（%） | 36.8 | 40.6 | 34.1 | 31.0 | | 归母净利润 | 34 | 173 | 335 | 528 | | 增长率（%） | 108.8 | 416.4 | 93.3 | 57.7 | | EPS | 0.08 | 0.39 | 0.75 | 1.18 | | P/E | 622 | 120 | 62 | 40 | | P/B | 25.0 | 9.7 | 8.4 | 6.9 | 资料来源：Wind，国联民生证券研究所预测（注：股价为 2026 年 02 月 27 日收盘价,汇率 1HKD ...

[Table_Author] | 分析师 | 张金洋 | | --- | --- | | 执业证书： S0590525120012 | | | 邮箱： | zhangjinyang@glms.com.cn | | 分析师 | 杨芳 | | 执业证书： S0590525120006 | | | 邮箱： | fangyang@glms.com.cn | 相对走势 百奥赛图-B（2315.HK）2025 年业绩快报点评 海外拓展+国内回暖驱动主业增长，全年业绩表现靓丽 glmszqdatemark [盈利预测与财务指标 Table_Forcast] 风险提示：海外经营风险，抗体开发不及预期风险，模式动物品系迭代风险。 | 单位/百万人民币 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入 | 980 | 1,379 | 1,849 | 2,422 | | 增长率（%） | 36.8 | 40.6 | 34.1 | 31.0 | | 归母净利润 | 34 | 173 | 335 | 528 | | 增长率（%） | 108 ...

2、百奥赛图(北京)医药科技股份有限公司于2025-12-10上市，公司主营业务为从事提供基因编辑服务、 临床前药理药效评估服务、模式动物销售、抗体开发及创新药开发。 3、百奥赛图(北京)医药科技股份有限公司是一家主要从事药物开发业务及临床前研究的公司。该公司 通过五个分部开展业务。 来源：新浪证券-红岸工作室 2月26日，百奥赛图涨8.15%，成交额2.11亿元，换手率7.92%，总市值346.39亿元。 异动分析 AI智能体+科创次新股+CRO概念+人民币贬值受益+注册制次新股 1、2026年1月13日互动易：我们通过AI的本地化部署，正在建设抗体药物研发AI智能体。随着千鼠万 抗计划与AI系统深度整合的持续推进，我们将为全球药企提供更加高效的研发工具和更为丰富的抗体 分子库，帮助药企伙伴提高临床前PCC分子的研发效率，这也将推动抗体发现业务迈入全新发展阶段。 区间今日近3日近5日近10日近20日主力净流入218.42万-921.89万-975.39万2306.19万7132.04万 公司简介 4、根据2024年年报，公司海外营收占比为67.94%，受益于人民币贬值。 5、百奥赛图(北京)医药科技股份有限 ...

Core Insights - The company Baiaosaitu-B (02315) has reported impressive performance forecasts, with significant progress in external licensing collaborations, leading institutions to be optimistic about its long-term growth potential [1] Financial Performance - For the fiscal year 2025, the company anticipates revenue between 1.369 billion and 1.389 billion yuan, representing a year-on-year growth of 39.61% to 41.65% [2] - The expected net profit attributable to shareholders is projected to be between 162 million and 182 million yuan, showing a substantial year-on-year increase of 384.26% to 443.88% [2] Business Developments - Since 2025, the company has secured significant external licensing agreements with leading domestic and international pharmaceutical companies, including a global licensing agreement for antibody molecules with BeiGene in July 2025 and full human antibody licensing for the RenMice platform with Merck in September 2025 [3] - These licensing agreements are expected to generate milestone payments and contribute to future growth [3] Institutional Perspectives - Research reports from institutions such as Guolian Minsheng Securities highlight the company's innovative advantages in model animals and preclinical CRO business, along with the "Thousand Mice, Ten Thousand Antibodies" initiative, which is expected to drive outstanding performance and open up long-term growth potential through external licensing [4] Stock Performance - The company was added to the Hong Kong Stock Connect eligible securities list on December 24, 2025, which may enhance investor attention and trading activity [5]

Core Viewpoint - The company BaiO Saite-B (02315) has seen a significant stock increase of over 6% following the release of its 2025 performance forecast, indicating strong growth potential in revenue and net profit [1] Group 1: Financial Performance - BaiO Saite-B forecasts annual revenue for 2025 to be approximately 1.369 billion to 1.389 billion yuan, representing a year-on-year growth of 39.61% to 41.65% [1] - The expected net profit attributable to shareholders is projected to be around 162 million to 182 million yuan, showing a substantial year-on-year increase of 384.26% to 443.88% [1] Group 2: Market Position and Growth Drivers - According to Guolian Minsheng Securities, the company's strong performance is attributed to its innovative advantages in model animals and preclinical CRO business, as well as the antibody platform supported by the "Thousand Mice and Ten Thousand Antibodies" initiative [1] - The company has established partnerships with several leading domestic and international pharmaceutical companies since 2025, and multiple pipelines have received IND approvals, which are expected to generate milestone payments and further enhance growth potential [1]

Core Viewpoint - Baosai Tu-B (02315) has shown a significant increase in stock price, rising over 6% following the release of its 2025 performance forecast, indicating strong growth potential in revenue and net profit [1] Group 1: Financial Performance - The company forecasts a revenue of approximately 1.369 billion to 1.389 billion yuan for 2025, representing a year-on-year growth of 39.61% to 41.65% [1] - Expected net profit attributable to shareholders is projected to be between 162 million to 182 million yuan, reflecting a substantial year-on-year increase of 384.26% to 443.88% [1] Group 2: Business Drivers - Guolian Minsheng Securities highlights the company's innovative advantages in model animals and preclinical CRO business, as well as the strengths of its antibody platform supported by the "Thousand Mice, Ten Thousand Antibodies" initiative [1] - Since 2025, the company has established external licensing agreements with several leading domestic and international pharmaceutical companies, and multiple pipelines have received IND approvals, which are expected to contribute to milestone payments and further revenue growth [1]

Core Viewpoint - Baosai Technology-B (02315) has shown a significant increase in stock price, rising over 6% following the release of its 2025 performance forecast, indicating strong growth potential in revenue and net profit [1] Financial Performance - The company expects to achieve revenue of approximately 1.369 billion to 1.389 billion yuan for the year 2025, representing a year-on-year growth of 39.61% to 41.65% [1] - The anticipated net profit attributable to shareholders is projected to be around 162 million to 182 million yuan, reflecting a substantial year-on-year increase of 384.26% to 443.88% [1] Market Position and Growth Drivers - Guolian Minsheng Securities highlighted that Baosai Technology benefits from its innovative advantages in model animals and preclinical CRO business, as well as the antibody platform supported by the "Thousand Mice and Ten Thousand Antibodies" initiative [1] - The company has established partnerships with several leading domestic and international pharmaceutical companies since 2025, and multiple pipelines have received IND approvals, which are expected to contribute to milestone payments and further revenue growth [1]

Core Viewpoint - Company is rated "Buy" by Guotai Junan Securities, highlighting its position as a leading global preclinical CRO and biotechnology firm with strong technical barriers and stable revenue growth from preclinical products and services [1] Group 1: Revenue Growth and Business Model - Preclinical products and services are the foundation of the company's business, with revenue growing rapidly; model animal sales are projected to increase from 66 million yuan in 2021 to 389 million yuan in 2024, with a CAGR exceeding 50% [1] - The company has established long-term partnerships with over 950 global collaborators, including the top ten pharmaceutical companies, completing over 6,350 drug evaluation projects [1] - The company has a strong overseas presence, with higher average order values from international clients compared to domestic ones, enhancing its risk resistance and profitability [1] Group 2: Antibody Development and Growth Engine - The "Thousand Mice and Ten Thousand Antibodies" plan is entering a realization phase, with antibody development and licensing becoming a significant growth driver; revenue from antibody development is expected to grow from 127 million yuan in 2022 to 318 million yuan in 2024, with a CAGR of 58% [2] - The company’s innovative "antibody shelf" model breaks traditional efficiency bottlenecks in antibody development, providing high-quality antibody molecules for global partners and maximizing technical value through various collaboration models [2] - The core pipeline focuses on high-value areas, complementing collaborative pipelines and gradually realizing commercial potential, thus creating a new growth engine [2] Group 3: Catalysts - Sales of model animals are expected to exceed forecasts, and the antibody licensing business is anticipated to realize results beyond expectations [3]

Core Viewpoint - Guolian Minsheng Securities initiates coverage on Baiaosaitu (02315) with a "recommended" rating, highlighting the company's three major business segments experiencing high growth and industry prosperity, alongside significant financial relief from fundraising efforts as the "Thousand Mice and Ten Thousand Antibodies" plan achieves milestones [1] Group 1: Model Animals - The company dominates the humanized mouse market with over 1,700 strains, contributing significantly to core profits, with a projected sales revenue of 257 million yuan from humanized mice sales and licensing by H1 2025, accounting for 94% of revenue [1] - The sales CAGR for model animals is expected to be 51.6% from 2022 to 2024, with increasing customer repurchase rates [1] - By 2024, overseas sales of model animals are projected to account for 56.4%, with a mature U.S. subsidiary facilitating rapid order acquisition [1] Group 2: Preclinical CRO Services - The preclinical CRO services segment, which extends from model animals, has an overseas revenue share of 79%, with strong growth certainty amid a recovering investment environment [2] - The pharmacology and efficacy team operates across Beijing, Haimen, and the U.S., having completed over 6,350 drug evaluation projects for approximately 950 global partners by H1 2025 [2] - Revenue for this segment reached 155 million yuan in H1 2025, reflecting a year-on-year growth of over 90%, driven by industry prosperity and a significant increase in client numbers [2] Group 3: Antibody Molecule Transfer/Authorization - The revenue model based on upfront payments, milestones, and sales sharing allows for stepwise revenue growth as pipelines advance, significantly reducing uncertainty for pharmaceutical companies [3] - The "Thousand Mice and Ten Thousand Antibodies" plan has created a vast array of antibody formats, positioning the company as a potential global source of new drug development [3] - By H1 2025, the company has signed 61 transfer/authorization/co-development projects with renowned pharmaceutical companies, with a projected CAGR of 58.3% for this segment from 2022 to 2024 [3]

Investment Rating - The investment rating for the company is positioned in the mid-to-lower range, with an AHP score of 2.38, placing it in the 38.9% percentile of the overall score [2][5]. Core Insights - The company, Baiaosaitu, is a leading preclinical CRO and biotechnology firm, focusing on gene editing, model animal sales, preclinical pharmacology and efficacy evaluation services, and antibody development. The gene editing technology is a significant foundation for its business, having developed proprietary CRISPR/EGE technology that enhances gene editing efficiency by nearly 20 times, significantly reducing commercial application costs [2][12]. - The company has expanded its business into innovative model animal sales, having developed over 4,300 gene-edited animals and cell models, including more than 1,700 humanized mice. The establishment of a production center compliant with AAALAC international standards supports large-scale breeding and supply of model animals [12][30]. - The company has established a comprehensive pharmacology and efficacy evaluation system, serving approximately 950 partners globally and completing over 6,350 drug evaluation projects. It has collaborations with 9 of the top 10 global pharmaceutical companies in the pharmacology and efficacy sector [2][18]. Summary by Sections AHP Score and Expected Allocation Ratio - The AHP score for Baiaosaitu is 2.38, indicating a mid-to-lower performance level in the AHP model [5][6]. Company Fundamentals and Highlights - Baiaosaitu has built platforms for gene editing, model animal breeding, preclinical pharmacology evaluation, and antibody drug development, evolving from a single-service biotechnology company to a leading biopharmaceutical enterprise [6][12]. - The company’s revenue composition shows that model animal sales accounted for approximately 44% of total revenue in the first half of 2025, followed by antibody development and preclinical pharmacology services [7][8]. Financial Comparison with Peers - From 2022 to the first half of 2025, Baiaosaitu's revenue was lower than that of comparable companies, with revenues of 5.34, 7.17, 9.80, and 6.21 billion yuan respectively. However, the net profit turned positive in 2024, with a net profit margin that improved over time [22][24]. - The company’s gross margin was relatively high, with figures of 73.38%, 70.59%, 77.67%, and 74.39% from 2022 to the first half of 2025, outperforming the average of comparable companies [24][25]. Fundraising Projects and Development Vision - The company plans to raise funds for projects including the construction of a drug early research service platform, antibody drug research and evaluation projects, and preclinical research projects, which are expected to enhance its core competitiveness and solidify its industry position [30][31].